{
    "aliases": [
        {
            "type": "Synonym",
            "name": "trastuzumab biosimilar GB221"
        },
        {
            "type": "USBrandName",
            "name": "Kanjinti"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab-anns"
        },
        {
            "type": "USBrandName",
            "name": "Ontruzant"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab-dttb"
        },
        {
            "type": "USBrandName",
            "name": "Trazimera"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab-qyyp"
        },
        {
            "type": "CodeName",
            "name": "ABP 980"
        },
        {
            "type": "Synonym",
            "name": "anti-c-erB-2"
        },
        {
            "type": "Synonym",
            "name": "anti-c-erbB2 monoclonal antibody"
        },
        {
            "type": "Synonym",
            "name": "anti-ERB-2"
        },
        {
            "type": "Synonym",
            "name": "anti-erbB-2"
        },
        {
            "type": "Synonym",
            "name": "anti-erbB2 monoclonal antibody"
        },
        {
            "type": "Synonym",
            "name": "anti-HER2/c-erbB2 monoclonal antibody"
        },
        {
            "type": "Synonym",
            "name": "anti-p185-HER2"
        },
        {
            "type": "LexicalVariant",
            "name": "HER2 monoclonal antibody"
        },
        {
            "type": "USBrandName",
            "name": "Herceptin"
        },
        {
            "type": "Synonym",
            "name": "Herceptin biosimilar PF-05280014"
        },
        {
            "type": "Synonym",
            "name": "Herceptin trastuzumab biosimilar PF-05280014"
        },
        {
            "type": "Abbreviation",
            "name": "MOAB HER2"
        },
        {
            "type": "Synonym",
            "name": "MOAB HER2"
        },
        {
            "type": "Synonym",
            "name": "monoclonal antibody HER2"
        },
        {
            "type": "Synonym",
            "name": "monoclonal antibody c-erb-2"
        },
        {
            "type": "USBrandName",
            "name": "Ogivri"
        },
        {
            "type": "CodeName",
            "name": "PF-05280014"
        },
        {
            "type": "Abbreviation",
            "name": "rhuMAb HER2"
        },
        {
            "type": "CodeName",
            "name": "RO0452317"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab biosimilar PF-05280014"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab biosimilar ABP 980"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab biosimilar SB3"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab biosimilar HLX02"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab biosimilar ALT02"
        },
        {
            "type": "Synonym",
            "name": "trastuzumab biosimilar EG12014"
        },
        {
            "type": "USBrandName",
            "name": "Herzuma"
        },
        {
            "type": "INDCode",
            "name": "6667"
        },
        {
            "type": "NSCNumber",
            "name": "688097"
        }
    ],
    "definition": {
        "html": "A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas.",
        "text": "A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas."
    },
    "drugInfoSummaryLink": {
        "uri": "https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab",
        "text": "Trastuzumab"
    },
    "nciConceptId": "C1647",
    "nciConceptName": "Trastuzumab",
    "termId": 42265,
    "name": "trastuzumab",
    "firstLetter": "t",
    "type": "DrugTerm",
    "termNameType": "PreferredName",
    "prettyUrlName": "trastuzumab"
}